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Abstract: This multicenter retrospective cohort study compared the effectiveness and safety of
long-term tafluprost, travoprost, or latanoprost in patients with primary open-angle glaucoma
(POAG) or normal-tension glaucoma (NTG). Data were extracted from electronic medical records of
300 patients treated with tafluprost, travoprost, or latanoprost for >6 months. Propensity matching
for age and sex was used for effectiveness and safety comparisons. The primary endpoint was visual
field (VF) progression via mean deviation (MD) slope. Secondary endpoints were change of MD,
intraocular pressure, pattern standard deviation, VF index, and advanced glaucoma intervention
study score. Treatment-related adverse events (AEs) were also compared between groups. Overall,
216 POAG or NTG patients were matched into Match Set 1 (72 patients/group), and 177 NTG-only
patients in Match Set 2 (59 patients/group) according to: age (mean: 61, 62 years) and sex (male:
53, 56%). There were no statistically significant between-group differences regarding MD slope
(p = 0.413, p = 0.374 in Match Sets 1 and 2, respectively). There were no significant between-group
differences/tendencies regarding secondary endpoints. No AEs were serious, and there were no
significant between-group differences regarding reported AEs. In patients with POAG or NTG,
long-term tafluprost, travoprost, or latanoprost showed similar effects. All three prostaglandin
analogs had good long-term safety profiles.
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1. Introduction
Glaucoma is a progressive optic neuropathy that causes optic nerve head and visual
field (VF) loss. Elevated intraocular pressure (IOP) is considered the principal and only
modifiable risk factor for glaucoma, and it is often given a significant role during treatment
decisions [1]. Besides IOP, many factors such as age, myopia, metabolic syndrome, etc.
are known to involved as risk factors in the pathogenesis of glaucoma [2]. Given that
hazards from exposure or accumulation of the effects of risk factors increase over time,
the incidence of primary open-angle glaucoma (POAG) is expected to increase continually
as life expectancy extends globally. In Korea and Japan, normal-tension glaucoma (NTG;
IOP ≤ 21 mmHg) is the most commonly reported type of glaucoma [3,4]. It was reported
that the NTG prevalence was 77% among OAG patients in Korea in the Namil Study, and
the NTG prevalence was 92% in Japanese patients in the Tajimi Study [4]. In NTG patients,
glaucoma damage occurs despite IOP being within the normal range, and it is reported
that the progression of glaucoma can be further delayed with additional IOP lowering [5].
Prostaglandin analogs (PGAs) have been shown to be the most popular first-line
treatment [6]. Moreover, the role of latanoprost in VF preservation has been recognized [7].
Indeed, this UKGTS trial showed that incident progression was reduced by 41% with the
use of latanoprost [7]. A recent study reported that the most widely prescribed treatment
of choice for NTG in Korea was PGA monotherapy [8,9]. Commercially available PGAs
are tafluprost, travoprost, and latanoprost. There are known variances in clinical efficacy
among these PGAs [10], and there is currently a lack of comparative clinical evidence be-
tween various PGA products in the real world regarding their effectiveness and tolerability,
especially with long-term use.
This study explores the comparative real-world effectiveness of long-term treatment
with widely used PGA products—tafluprost, travoprost, or latanoprost—on IOP reduction
and various indices for monitoring the status of glaucomatous VF progression in NTG
patients using data collected from standard automated perimetry throughout 10 tertiary
hospitals in Korea.
2. Materials and Methods
2.1. Ethics and Consent
The study protocol was approved by the Institutional Review Board (IRB) committee
of each study center, following the principles of the Declaration of Helsinki. The require-
ment to obtain patients’ informed consent was waived, based on the premise that data
confidentiality was well maintained and patient privacy was adequately protected.
2.2. Study Design and Patients
This was a retrospective, multicenter (10 sites in South Korea) cohort study to in-
vestigate and compare the long-term effect of three PGA ophthalmic solutions: 0.0015%
tafluprost, 0.004% travoprost, and 0.005% latanoprost, in patients with POAG or NTG
(Figure 1). Data were collected retrospectively from electronic medical records (EMRs)
for patients with POAG or NTG who received PGA ophthalmic solutions as primary
monotherapy as initial treatment between January 2010 and June 2016. Study participants
were included sequentially from the date of IRB study approval for chart review. Match
Set 1 was selected by matching age and sex based on the lowest number of control groups
in the full analysis set (FAS) in patients with POAG or NTG. Similarly, Match Set 2 was
selected by matching the FAS in patients with NTG. The method of selecting the match
set was the SAS macro, percentage match (optimum algorithm) method of Bergstralh and
Kosanke [11].
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Figure 1. Study flow. 
Inclusion criteria included: (1) aged 19 years or older, (2) diagnosis of POAG or NTG, 
(3) history of administering one of the three above-mentioned PGA ophthalmic solutions 
to be used in this study before study initiation and existence of at least five reliable VF 
data points measured with Humphrey perimeter. Exclusion criteria included: (1) history 
of filtration or any other ocular surgery, (2) presence of pathologies that may affect VF test 
results, (3) additional administration of medications that may affect IOP during the study 
period, such as corticosteroids, calcium channel blockers, angiotensin-2 receptor blocker, 
dorzolamide, or brimonidine, (4) dosage change of concomitant treatments that have been 
received and could substantially impact IOP or VF. 
Additionally, the NTG diagnosis for selection of Match Set 2 was based on the fol-
lowing criteria: (1) typical glaucomatous optic neuropathy with corresponding VF loss; 
(2) open anterior chamber angles; (3) normal untreated IOP level (≤21 mmHg). Glaucoma-
tous optic neuropathy was determined based on characteristic optic disc and/or retinal 
nerve fiber layer (RNFL) changes, such as the presence of diffuse or localized rim thinning, 
rim notching, and an RNFL defect. Typical glaucomatous VF defects, which were assessed 
by a Humphrey automated perimetry (Swedish Interactive Threshold Algorithm [SITA], 
standard 24-2/30-2 program) on two occasions, were made based on Anderson’s criteria: 
(1) the Glaucoma Hemifield Test (GHT) is “outside normal limits”, (2) three contiguous 
non-edge points on the pattern deviation plot within the Bjerrum’s area with p < 0.05, one 
of which is p < 0.01, and (3) pattern standard deviation (PSD) with p < 0.05 [12]. Glaucoma 
severity was divided into early, moderate, and severe according to mean deviation (MD) 
value (early; >−6 decibel (dB); moderate −6~−12 dB, severe; <−12 dB) [13]. 
2.3. Statistical Analysis 
The analysis of efficacy was performed on Match Sets 1 and 2 with last observation 
carried forward (LOCF). The analysis of safety was performed on the safety set (all sub-
jects enrolled in this study). 
The primary objective of the study was to evaluate the rates of VF progression via 
MD slope expressed in dB/year. Secondary objectives were changes in other VF parame-
ters, including MD, IOP, PSD, VF index (VFI), and the advanced glaucoma intervention 
Figure 1. Study flow.
Inclusion criteria included: (1) aged 19 years or older, (2) diagnosis of POAG or NTG,
(3) history of administering one of the three above-mentioned PGA ophthalmic solutions
to be used in this study before study initiation and existence of at least five reliable VF
data points measured with Humphrey perimeter. Exclusion criteria included: (1) history of
filtration or any other ocular surgery, (2) presence of pathologies that may affect VF test
results, (3) additional administration of medications that may affect IOP during the study
period, such as corticosteroids, calcium channel blockers, angiotensin-2 receptor blocker,
dorzolamide, or brimonidine, (4) dosage change of concomitant treatments that have been
received and could substantially impact IOP or VF.
Additionally, the NTG diagnosis for selection of Match Set 2 was based on the fol-
lowing criteria: (1) typical glaucomatous optic neuropathy with corresponding VF loss;
(2) open anterior chamber angles; (3) normal untreated IOP level (≤21 mmHg). Glaucoma-
tous optic neuropathy was determined based on characteristic optic disc and/or retinal
nerve fiber layer (RNFL) changes, such as the presence of diffuse or localized rim thinning,
rim notching, and an RNFL defect. Typical glaucomatous VF defects, which were assessed
by a Humphrey automated perimetry (Swedish Interactive Threshold Algorithm [SITA],
standard 24-2/30-2 program) on two occasions, were made bas d n Anderson’s criteria:
(1) the Glaucoma Hemifield Test (GHT) is “outside normal limits”, (2) three contiguous
non-edge points on the pattern deviation plot within the Bjerrum’ area with p < 0.05, ne
of which is p < 0.01, and (3) pattern standard deviation (PSD) with p < 0.05 [12]. Glaucoma
sever ty was divided into early, moderate, and severe according to mean deviation (MD)
value (early; >−6 dec bel (dB); moderate −6~−12 dB, seve e; <−12 dB) [13].
2.3. Statistical Analysis
The analysis of efficacy was performed on Match Sets 1 and 2 with last observation
carried forward (LOCF). The analysis of safety was performed on the safety set (all subjects
enrolled in this study).
The primary objective of the study was to evaluate the rates of VF progression via MD
slope expressed in dB/year. Secondary objectives were changes in other VF parameters,
including MD, IOP, PSD, VF index (VFI), and the advanced glaucoma intervention study
(AGIS) score from baseline. MD, PSD, VFI, and AGIS score [14] were evaluated using
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the parameters from Humphrey perimetry analyzer. In addition, all adverse events (AEs)
reported in the EMRs were recorded for safety and tolerability evaluation.
In this study, a propensity matching approach was used to balance two major con-
founding factors between the groups: age and sex. Baseline characteristics were reported
in mean ± SD or number of patients (%). Comparisons of continuous and categorical vari-
ables between the three treatment groups were performed by analysis of variance (ANOVA)
and Chi-square tests, respectively. The first time that functional deterioration was found
was regarded as the endpoint in survival analyses. p values less than 0.05 were considered
statistically significant. All statistical analyses were conducted using SAS software (SAS
Institute, Cary, NC, USA) V9.4.
3. Results
A review of EMRs identified 299 eligible patients (tafluprost, n = 110; travoprost; n = 73;
latanoprost, n = 117), who started their first treatment for POAG or NTG between January
2010 and June 2016. Of these, adjustment for age and sex differences between groups using
the propensity matching approach resulted in 216 (72.24% of the FAS) patients were included
in Match Set 1 (Figure 2). A total of 262 NTG patients were enrolled in the NTG group,
and 261 patients were included in the FAS. Of these, 177 (67.82% of the FAS) patients were
included in Match Set 2 (Figure 2). The follow-up duration of Match 1 was 4.92 ± 0.27 years
(3.5~5 years) in the tafluprost group, 4.85 ± 0.42 years (3.0~5 years) in the travoprost group,
and 4.98 ± 0.1 years (4.5~5 years) in the latanoprost group. The follow-up duration of Match
2 was 4.92 ± 0.26 years (3.5~5 years), 4.87 ± 0.34 years (3.5~5 years), and 4.97 ± 0.13 years
(4.5~5 years) in the tafluprost, travoprost, and latanoprost groups, respectively.
Table 1 compares the demographic and clinical characteristics of the three subgroups
(tafluprost, travoprost, and latanoprost groups) in Match Sets 1 and 2. In Match Set 1,
38 (52.78%) of the subjects who participated in this study were men in the three sub-
groups, respectively. The average age was 61.04 ± 10.64 years in the tafluprost group,
63.24 ± 11.66 years in the travoprost group, and 61.76 ± 11.17 years in the latanoprost group.
Table 1. Clinical characteristics of POAG or NTG patients (Match Set 1) and NTG patients only (Match Set 2).













Age (years) 61.04 ± 10.64 63.24 ± 11.66 61.76 ± 11.17 60.27 ± 11.04 61.83 ± 11.98 61.39 ± 11.86
Gender, n (%)
Female 34 (47.22) 34 (47.22) 34 (47.22) 26 (44.07) 26 (44.07) 26 (44.07)
Glaucoma Type, n (%)
NTG (IOP < 21 mmHg) 65 (90.28) 59 (81.94) 63 (87.50)
Glaucoma Stage, n (%)
Early (MD > −6 dB) 53 (73.61) 48 (66.67) 51 (70.83)
Moderate 12 (16.67) 17 (23.61) 7 (9.72)
Advanced (MD < −12 dB) 7 (9.72) 7 (9.72) 14 (19.44)
MD at initial visit (dB) −5.02 ± 4.81 −5.44 ± 4.64 −5.50 ± 5.80 −5.06 ± 4.95 −5.41 ± 4.82 −6.08 ± 6.19
Baseline IOP (mmHg) 15.18 ± 3.28 14.67 ± 2.83 15.54 ± 3.96 15.18 ± 3.30 14.49 ± 2.74 14.98 ± 3.67
Note: Data presented as mean ± SD. Abbreviations: IOP: intraocular pressure; MD: mean deviation; NTG: normal-tension glaucoma;
POAG: primary open-angle glaucoma; SD: standard deviation.
In Match Set 2, ages were 60.27 ± 11.04, 61.83 ± 11.98, and 61.39 ± 11.86 years for
tafluprost, travoprost, and latanoprost, respectively. Regarding sex, the proportion of males
in the tafluprost, travoprost, and latanoprost arms was 55.93%, respectively.
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Figure 2. Disposition of POAG or NTG patients (Match Set 1) or NTG-only patients (Match Set 2).
3.1. Effectiveness
Mean changes in MD slope and MD, IOP, PSD, VFI, and AGIS score from the initial
visit to the last visit are presented in Table 2.
In Match Set 1, the MD slope was 0.04 ± 0.51, −0.07 ± 0.54, 0.02 ± 0.39 dB/year for
tafluprost, travoprost, and latanoprost, respectively, and there was no statistically signifi-
cant difference between the three groups (p = 0.413). There were changes (mean ± SD) at the
last visit compared to the initial visit; IOP −1.89 ± 2.77, −2.11 ± 2.16, −2.02 ± 2.88 mmHg;
VFI −1.46 ± 4.85, −2.53 ± 9.01, −0.46 ± 5.27; AGIS score 0.00 ± 3.45, 0.00 ± 3.39,
−0.06 ± 2.00 for tafluprost, travoprost, and latanoprost, respectively. Furthermore, of
these, there was no statistically significant difference between the three groups (p = 0.898,
0.255, 0.991) (Table 2).
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Table 2. Comparisons of endpoint change between the three PGAs in patients with POAG or NTG patients (Match Set 1)
and NTG patients only (Match Set 2). All data are presented as mean ± standard deviation.












(n = 59) p-Value
†
IOP (mmHg)
Initial visit 15.18 ± 3.30 14.49 ± 2.74 14.98 ± 3.67 - 15.69 ± 3.11 14.49 ± 2.74 14.74 ± 3.53 -
Last visit 13.29 ± 1.78 12.36 ± 2.07 12.97 ± 2.67 - 13.49 ± 1.96 12.36 ± 2.07 12.93 ± 2.67 -
Change −1.89 ± 2.77 −2.11 ± 2.16 −2.02 ± 2.88 0.898 −2.20 ± 2.64 −2.11 ± 2.16 −1.86 ± 2.95 0.765
MD (dB)
Initial visit −4.63 ± 4.40 −5.41 ± 4.82 −5.66 ± 5.94 - −5.06 ± 4.95 −5.41 ± 4.82 −6.08 ± 6.19 -
Last visit −4.50 ± 4.83 −5.78 ± 5.28 −5.58 ± 6.18 - −4.85 ± 4.85 −5.78 ± 5.28 −5.88 ± 6.35 -
Change 0.14 ± 2.48 −0.38 ± 2.63 0.08 ± 1.96 0.432 0.21 ± 2.86 −0.38 ± 2.63 0.20 ± 2.40 0.390
MD Slope
(dB/year) 0.04 ± 0.51 −0.07 ± 0.54 0.02 ± 0.39 0.413 0.05 ± 0.59 −0.07 ± 0.54 0.04 ± 0.48 0.374
PSD (dB)
Initial visit 5.67 ± 4.01 6.25 ± 4.06 6.53 ± 4.40 - 5.96 ± 4.17 6.25 ± 4.06 6.68 ± 4.36 -
Last visit 5.92 ± 4.06 6.35 ± 4.18 6.54 ± 4.24 - 6.36 ± 4.17 6.35 ± 4.18 6.44 ± 4.21 -
Change 0.26 ± 2.13 0.10 ± 1.90 0.00 ± 1.67 0.751 0.40 ± 2.18 0.10 ± 1.90 −0.24 ± 1.85 0.215
VFI
Initial visit 87.74 ± 12.73 87.00 ± 13.95 87.60 ± 14.06 - 87.60 ± 13.88 87.00 ± 13.95 86.43 ± 14.78 -
Last visit 88.45 ± 12.37 84.69 ± 16.28 85.11 ± 17.53 - 87.55 ± 12.69 84.69 ± 16.28 84.54 ± 18.20 -
Change −1.46 ± 4.85 −2.53 ± 9.01 −0.46 ± 5.27 0.255 −1.14 ± 6.16 −2.53 ± 9.01 0.23 ± 7.13 0.171
AGIS Score
Initial visit 3.72 ± 4.53 5.08 ± 5.64 4.70 ± 5.36 - 4.05 ± 4.87 5.08 ± 5.64 5.19 ± 5.22 -
Last visit 3.72 ± 4.50 5.08 ± 5.67 4.63 ± 5.66 - 3.88 ± 4.51 5.08 ± 5.67 4.83 ± 5.40 -
Change 0.00 ± 3.45 0.00 ± 3.39 −0.06 ± 2.00 0.991 −0.17 ± 3.87 0.00 ± 3.39 −0.36 ± 2.52 0.843
† ANOVA p-value. MD (median deviation) slope. Data are presented as mean ± SD unless stated otherwise. AGIS: Advanced Glaucoma
Intervention Study (worsening is defined by at least 2 units of AGIS score or by at least 2 decibels of MD); IOP: intraocular pressure; MD:
mean deviation; NTG: normal-tension glaucoma; PGA: prostaglandin analog; POAG: primary open-angle glaucoma; PSD: pattern standard
deviation; SD: standard deviation; VFI: visual field index.
In Match Set 2, the MD slope was 0.05 ± 0.59, −0.07 ± 0.54, 0.04 ± 0.48 dB/year
for tafluprost, travoprost, and latanoprost, respectively. During the study, MD remained
relatively stable over time, and no statistically significant difference was observed in any of
the three groups (p = 0.374) (Figure 3 and Table 2).
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There were changes (mean ± SD) at the last visit compared to the initial visit: IOP
−2.20 ± 2.64, −2.11 ± 2.16, −1.86 ± 2.95 mmHg; VFI −1.14 ± 6.16, −2.53 ± 9.01,
0.23 ± 7.13; AGIS Score −0.17 ± 3.87, 0.00 ± 3.39, −0.36 ± 2.52 for tafluprost, travoprost,
and latanoprost, respectively. Furthermore, of these, there were no statistically significant
differences between the three groups (p = 0.765, 0.171, 0.843) (Table 2). In addition, IOP
showed a reduction after 1 year of treatment, and the reduced IOP remained stable until
the end of the study (Figure 4).
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Figure 4. Median deviation (left) and intraocular pressure (right)–time curves in patients diagnosed with NTG, who
received long-term treatment with three PGAs (tafluprost (n = 58), travoprost (n = 58) or latanoprost (n = 58)) and completed
the study (Match Set 2).
Overall, there were no sig ificant tendencies between the three groups regarding the
change in MD, PSD, and VFI, in Match Sets 1 and 2 (Table 2).
3.2. Safety
The e were reported AEs; 13 cases from 8/110 patients in the tafluprost group, 20 cases
from 9/73 patients in the travoprost group, and 11 cases from 10/117 patients in the
latanoprost group (Table 3). The most frequently reported AEs were eye disorders in each
group (11, 7, and 8 cases in the tafluprost, travoprost, and latanoprost arms, respectively),
and all AEs were not serious. There were no significant between-group differences.
Table 3. Ocular adverse events in patients receiving long-term treatment with tafluprost, travoprost, or latanoprost (safety set).
Preferred Term Tafluprost Travoprost Latanoprost
Abnormal sensation in eye 0 1 0
Cata act 0 0 2
Cerebral rteriosclerosis 0 1 0
Chalazio 1 1 0
Chest pain 0 1 0
Chronic gastritis 0 1 0
Ciliary hyperaemia 2 1 0
Conjunctival hyperaemia 2 0 0
Conjunctival irritation 1 0 0
Diabetes mellitus 0 1 0
Diarrhoea 0 1 0
Dry eye 2 0 0
Dyslipidaemia 0 1 0
Dyspepsia 0 1 0
J. Clin. Med. 2021, 10, 2717 8 of 12
Table 3. Cont.
Preferred Term Tafluprost Travoprost Latanoprost
Eye pain 0 1 1
Eye pruritus 1 0 1
Gastritis 0 1 0
Gastritis erosive 1 0 0
Haemorrhagic erosive gastritis 0 1 0
Headache 1 0 1
Helicobacter gastritis 0 1 0
Hypertension 0 0 1
Hyperuricaemia 0 1 0
Ichthyosis 0 0 1
Lacrimation increased 0 0 1
Macular degeneration 0 1 0
Ocular discomfort 1 0 0
Optic disc haemorrhage 0 1 1
Prurigo 0 1 0
Visual impairment 1 1 2
Vomiting 0 1 0
4. Discussion
This study demonstrated similar efficacy with respect to mean MD value and MD
slope from the baseline and safety among tafluprost, latanoprost, and travoprost groups
over the follow-up period. Although many clinical studies have compared the efficacy and
safety of two PGAs among the three, these studies also did not show consistent significant
differences between each of the PGAs in reducing IOP or progression of VF defects [15–18].
Previous clinical studies with relatively short-term follow-up have reported possible
variances in terms of IOP-lowering effect among different PGA products. Uusitalo et al.
reported that, after changing from latanoprost to a tafluprost formulation, tafluprost
exhibited a similar IOP-lowering effect and better tolerance [19]. Recently, Faseeh et al.
reported in POAG subjects that latanoprost, travoprost, and tafluprost show similar efficacy
in terms of reducing mean IOP and diurnal IOP fluctuation in subjects with POAG [20].
IOP is the most important factor associated with the progression of glaucoma. PGAs reduce
IOP through a mechanism that makes the extracellular matrix reconstruction to increase
the uveoscleral outflow facility of aqueous humor. PGA activates prostaglandin F2a, matrix
metalloproteins that are located in ciliary muscle and decompose collagens, resulting in
dilation of ciliary muscle, which lowers the resistance of uveoscleral outflow and increases
the outflow facility of aqueous humor, resulting in reduced IOP [21,22]. In our study
with long-term follow-up, no statistically significant differences were observed between
the three treatment groups in terms of IOP changes at the end of the follow-up period.
Some studies corroborate the fact that IOP still remains a major risk factor for structural or
functional change. Yoshikawa et al. suggested that mean IOP reduction is a key modifiable
factor to mitigate the risk of VF progression in NTG patients [23]. In the CNTGS study [24],
which has provided some of the most prominent evidence to support the need for robust
IOP reduction in NTG patients, it was reported that a 30% reduction in IOP resulted in
a significantly decreased risk for VF progression in glaucoma patients, regardless of low
baseline IOP. In a study of NTG patients receiving topical medical treatments [25], patients
with a higher mean IOP reduction from baseline (i.e., percentage IOP reduction > 22.1%)
experienced less progression than patients who achieved a lower mean IOP reduction (i.e.,
percentage IOP reduction < 13.3%). Wang and Singh suggested lowering IOP further as the
most effective way of slowing the progression of glaucoma in patients with low IOP [26].
In the present study, the mean IOP reduction from baseline in NTG patients for the three
PGAs, tafluprost, travoprost, latanoprost, was −2.20, −2.11, −1.86 mmHg, respectively,
which translates to a rate of IOP reduction of 14.03%, 14.70%, and 12.28%, respectively.
Although the rate of IOP reduction achieved in our study is lower than that observed
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in the above studies, the corresponding rate of VF progression among medically-treated
glaucoma patients in our study did not appear to be remarkable over a five-year period
of follow-up. It is thought that one of the reasons for the low level of IOP reduction was
that our subjects had low baseline IOP compared with previous studies. Considering that
glaucoma is caused by the stress of IOP that is higher than the IOP threshold that the optic
nerve and lamina cribrosa can tolerate, absolutely low IOP can certainly be seen as a factor
that prevented glaucoma progression. Given that glaucoma did not progress if the IOP
was <17 mmHg in POAG subjects [27], further studies about safe IOP in low-teen NTG
are needed.
Determining VF progression, which is the only functional test in glaucoma, is impor-
tant and related with the functional endpoint of new treatments for clinical trials and the
key to effective clinical disease management [28]. Monitoring the VF status of patients
is conducted after testing over a period of time. However, considering the variability
of the VF test, appropriate analysis of VF progression measurements requires a suitable
observation period and number of follow-up tests to achieve statistical power [29]. In
the Early Management Glaucoma Trial and Collaborative NTG study, the mean rate of
progression was −1.08 dB/year and −0.2 to −2 dB/year, respectively [23,30]. In a study by
Heijl et al., among glaucoma patients under clinical care, the mean rate of progression was
−0.80 dB/year [31]. The current study shows a lower degree of VF progression rate than
previous reports. None of the three groups appeared to exhibit a significant rate of MD
deterioration during the follow-up time in the current long-term study, and the difference
between the three groups did not reach statistical significance. This finding may reflect
limitations related to the follow-up duration, relatively small sample size, and a relatively
higher proportion of NTG patients included in the current study. It is also thought that the
fact that they were subjects who had been using the same drugs for a considerable period
of time without any problems may have also accounted for the findings. Another reason
may be that subjects in our study were relatively younger aged patients with early-stage
glaucoma. Since there were as an insufficient proportion of advanced-stage cases in our
study, subgroup evaluation by glaucoma stage was not feasible. In addition, the inclusion
of subjects with early-stage glaucoma who did not necessarily require treatment cannot be
excluded. According to the EMGT report, glaucoma severity (worse MD) is a risk factor
for glaucoma progression [30]. Furthermore, in the UKGTS study, only 34% of participants
in the untreated group showed VF progression during two years of follow-up [7]. In our
study, one reason for the low progression rate may be that most subjects included had
early-stage glaucoma. However, the EMGT report showed that the pressure reduction
decreased the risk by half. In addition, some studies showed that a significant number of
NTG patients did not progress even without treatment [32,33]. The initiation of treatment
in patients with early glaucoma may be controversial due to possible overtreatment. The
distinction between patients who will not progress without treatment and patients who
must be treated is an area where further research is needed.
PGAs are known to be the most efficacious drugs for reducing IOP, while this is
associated with higher rates of adverse reactions such as conjunctival hyperemia or deep
sulcus [34,35]. Of course, in our study, there were some cases with hyperpigmentation
and long cilia. However, there were no serious AEs which resulted in the need to stop
instillation of eyedrop. This may reflect the fact that our enrolled subjects had been using
the same drugs for a long time without serious complications.
The current study has several limitations. Basically, enrolled subjects in this study
had been using the same drugs for a long time without any serious problems. This design
might have had an effect on the results. It is known that both the frequency of changing
medication and poor medication adherence are glaucoma progression risk factors and,
hence, may have confounded the results [27,36]. Fajgenbaum and Ansari reported that
PGAs were the most popular first-line treatment in 73% of patients [6]. The mean duration
of follow-up was 56 months (24–180 months), and only 27% of patients required only
first-line therapy, and 52% of patients required at least third-line therapy during the course
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of their follow-up. Regarding safety parameters, all of the reported AEs, including patient
complaints from the EMRs, were collected for the current study. However, since the
information was collected retrospectively, some of the non-serious AEs, such as frequency
of conjunctival hyperemia and dry eye, were not clearly evaluated or may have been
missed. This can be considered one of the limitations of retrospective chart review studies.
However, the rather low frequency of reported AEs can also be interpreted as the relatively
infrequent occurrence of severe AEs that led to treatment discontinuation. Thus, we
have given more consideration to the effect on IOP lowering and VF progression than to
tolerability aspects. Long-term and large-scale prospective studies are needed to overcome
this point. Most of the subjects included had NTG; therefore, our results may not be
applicable for individuals with high-tension glaucoma. Due to the long follow-up and
retrospective design, unmanaged confounders such as self-medication, lifestyle, social-
economic status, could have influenced the results [37]. Additionally, patients who adhered
to the study the drug due to the positive drug response could have been selected for the
analysis. Considering the extensive period required for the current analysis, retrospective
design was selected as a rational approach from a practical point of view.
In conclusion, this multicenter, retrospective, cohort study demonstrated that, al-
though there are some nuanced differences, all three PGAs seem to allow robust and
comparable IOP reduction as well as no statistically significant differences on the indices re-
lated to the rate of VF progression in Korean glaucoma patients over a long-term follow-up
period during which all three PGAs showed sufficient VF preservation function alone. This
supports the postulate that the three PGA treatments are sufficient as a first-line treatment
in Koreans. Therefore, a future prospective clinical trial that compares the benefits of
switching to another PGA versus continuing the same PGA after a treatment period of
approximately three years or more, may be valuable.
Author Contributions: Conceptualization, J.-M.K. and C.-Y.K.; methodology, J.-M.K., K.-R.S., H.-
K.K., S.-W.P., E.-J.L., J.-W.J., H.-Y.L.P. and C.-Y.K.; formal analysis, J.-M.K.; investigation, J.-M.K. and
C.-Y.K.; resources, J.-M.K., K.-R.S., H.-K.K., S.-W.P., E.-J.L., J.-W.J., H.-Y.L.P., J.A., C.Y. and C.-Y.K.;
data curation, S.-W.P., E.-J.L., C.-Y.K. and J.A.; writing—original draft preparation, J.-M.K.; writing—
review and editing, J.-M.K., K.-R.S., H.-K.K., S.-W.P., E.-J.L., J.-W.J., H.-Y.L.P., J.A., C.Y. and C.-Y.K.;
visualization, J.-M.K. and K.-R.S.; supervision, C.-Y.K.; project administration, C.-Y.K.; funding
acquisition, C.-Y.K. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by Santen Pharmaceutical Korea Co., Ltd.
Institutional Review Board Statement: The study protocol was approved by the Institutional Review
Board (IRB) committee of each study center, following the principles of the Declaration of Helsinki.
The IRB registration number is KBSMC2018-02-012 (Kangbuk Samsung Hospital), 2018-0580 (Asan
Medical Center), 2018-02-006 (Kim’s Eye Hospital), CNUH-2018-056 (Chonnam National University
Hospital), B1804-462-401 (Seoul National University Bundang Hospital), H1802-036-922 (Seoul
National University Hospital), KC18REDI0174 (Seoul St Mary’s Hospital), AJIRB-MED-MDB-17-512
(Ajou University School of Medicine), 2018AN0078 (Korea University College of Medicine), and
4-2017-1242 (Severance Hospital).
Informed Consent Statement: The requirement to obtain patients’ informed consent was waived,
based on the premise that data confidentiality was well-maintained and patient privacy was ade-
quately protected.
Data Availability Statement: Restrictions apply to the availability of the dataset used in this study
as data were collected retrospectively from electronic medical records (EMRs) of participating study
sites; hence, they are available from the corresponding author upon reasonable request. The data are
not available publicly due to privacy and ethical restrictions.
Acknowledgments: Under the direction of the authors, editorial assistance was provided by David P.
Figgitt, ISMPP CMPP™, Content Ed Net, with funding from Santen Pharmaceutical Korea Co., Ltd.
Conflicts of Interest: The authors declare no conflict of interest.
J. Clin. Med. 2021, 10, 2717 11 of 12
References
1. Ahmed, O.M.; Waisbourd, M.; Spaeth, G.L.; Katz, L.J. Improvement in structure and visual function in patients with glaucoma:
The possible key to better treatment? Surv. Ophthalmol. 2020. [CrossRef]
2. Kim, K.E.; Kim, M.J.; Park, K.H.; Jeoung, J.W.; Kim, S.H.; Kim, C.Y.; Kang, S.W.; Epidemiologic Survey Committee of the Korean
Ophthalmological Society. Prevalence, Awareness, and Risk Factors of Primary Open-Angle Glaucoma: Korea National Health
and Nutrition Examination Survey 2008–2011. Ophthalmology 2016, 123, 532–541. [CrossRef] [PubMed]
3. Cho, H.K.; Kee, C. Population-based glaucoma prevalence studies in Asians. Surv. Ophthalmol. 2014, 59, 434–447. [CrossRef]
[PubMed]
4. Kim, K.E.; Park, K.H. Update on the Prevalence, Etiology, Diagnosis, and Monitoring of Normal-Tension Glaucoma. Asia Pac. J.
Ophthalmol. 2016, 5, 23–31. [CrossRef] [PubMed]
5. Ahrlich, K.G.; De Moraes, C.G.V.; Teng, C.C.; Prata, T.S.; Tello, C.; Ritch, R.; Liebmann, J.M. Visual field progression differences
between normal-tension and exfoliative high-tension glaucoma. Investig. Ophthalmol. Vis. Sci. 2010, 51, 1458–1463. [CrossRef]
[PubMed]
6. Fajgenbaum, M.; Ansari, E. Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective,
Non-Interventional, Single-Center UK Study. Adv. Ther. 2017, 34, 2033–2042. [CrossRef] [PubMed]
7. Garway-Heath, D.F.; Crabb, D.P.; Bunce, C.; Lascaratos, G.; Amalfitano, F.; Anand, N.; Azuara-Blanco, A.; Bourne, R.R.; Broadway,
D.C.; Cunliffe, I.A.; et al. Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial.
Lancet 2015, 385, 1295–1304. [CrossRef]
8. Kim, C.Y.; Park, K.H.; Ahn, J.; Ahn, M.-D.; Cha, S.C.; Kim, H.S.; Kim, J.M.; Kim, M.J.; Kim, T.-W.; Kim, Y.Y.; et al. Treatment
patterns and medication adherence of patients with glaucoma in South Korea. Br. J. Ophthalmol. 2017, 101, 801–807. [CrossRef]
[PubMed]
9. Han, Y.S.; Ha, A.; Kim, Y.K.; Jeoung, J.W.; Park, K.H. Normal-tension Glaucoma Management: A Survey of Glaucoma Sub-
specialists in Korea. Korean J. Ophthalmol. 2020, 34, 425–431. [CrossRef] [PubMed]
10. Takagi, Y.; Santo, K.; Hashimoto, M.; Fukuchi, T. Ocular hypotensive effects of prostaglandin analogs in Japanese patients with
normal-tension glaucoma: A literature review. Clin. Ophthalmol. 2018, 12, 1837–1844. [CrossRef] [PubMed]
11. Bergstralh, E.; Kosanke, J. Computerized Matching of Controls: Section of Biostatistics Technical Report 56; Mayo Foundation: Rochester,
MN, USA, 1995.
12. Yum, H.R.; Park, H.Y.L.; Park, C.K. Characteristics of Normal-tension Glaucoma Patients with Temporal Retinal Nerve Fibre
Defects. Sci. Rep. 2020, 10, 6362. [CrossRef]
13. Yousefi, S.; Mahmoudi Nezhad, G.S.; Pourahmad, S.; Vermeer, K.A.; Lemij, H.G. Distribution and Rates of Visual Field Loss
across Different Disease Stages in Primary Open-Angle Glaucoma. Ophthalmol. Glaucoma 2018, 1, 52–60. [CrossRef]
14. Rabiolo, A.; Morales, E.; Mohamed, L.; Capistrano, V.; Kim, J.H.; Afifi, A.; Yu, F.; Coleman, A.L.; Nouri-Mahdavi, K.; Caprioli,
J. Comparison of Methods to Detect and Measure Glaucomatous Visual Field Progression. Transl. Vis. Sci. Technol. 2019, 8, 2.
[CrossRef]
15. Song, J.E.; Lee, M.Y.; Chung, P.; Kim, J.M. The Long-term Effects of Prostaglandin Analogues on Central Corneal Thickness and
Intraocular Pressure. J. Korean Ophthalmol. Soc. 2020, 61, 650–657. [CrossRef]
16. Kim, J.M.; Park, S.W.; Seong, M.; Ha, S.J.; Lee, J.W.; Rho, S.; Lee, C.E.; Kim, K.N.; Kim, T.-W.; Sung, K.R.; et al. Comparison of the
Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost. Pharmaceuticals 2021,
14, 501. [CrossRef]
17. Schnober, D.; Hofmann, G.; Maier, H.; Scherzer, M.L.; Ogundele, A.B.; Jasek, M.C. Diurnal IOP-lowering efficacy and safety of
travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clin.
Ophthalmol. 2010, 4, 1459–1463. [CrossRef]
18. Tan, N.Y.Q.; Tham, Y.C.; Koh, V.; Nguyen, D.Q.; Cheung, C.Y.; Aung, T.; Wong, T.Y.; Cheng, C.Y. The Effect of Testing Reliability
on Visual Field Sensitivity in Normal Eyes: The Singapore Chinese Eye Study. Ophthalmology 2018, 125, 15–21. [CrossRef]
19. Uusitalo, H.; Chen, E.; Pfeiffer, N.; Brignole-Baudouin, F.; Kaarniranta, K.; Leino, M.; Puska, P.; Palmgren, E.; Hamacher, T.;
Hofmann, G.; et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Acta Ophthalmol. 2010, 88, 329–336. [CrossRef]
20. Faseeh, A.E.; Allam, R.S.; Shalash, A.B.; Abd Elmohsen, M.N. Comparison between Latanoprost, Travoprost, and Tafluprost in
reducing intraocular pressure fluctuations in patients with glaucoma. Eur. J. Ophthalmol. 2021, 1120672121990540. [CrossRef]
21. Lim, K.S.; Nau, C.B.; O’Byrne, M.M.; Hodge, D.O.; Toris, C.B.; McLaren, J.W.; Johnson, D.H. Mechanism of action of bimatoprost,
latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 2008, 115, 790–795.e794. [CrossRef]
22. Heo, J.Y.; Ooi, Y.H.; Rhee, D.J. Effect of prostaglandin analogs: Latanoprost, bimatoprost, and unoprostone on matrix metallo-
proteinases and their inhibitors in human trabecular meshwork endothelial cells. Exp. Eye Res. 2020, 194, 108019. [CrossRef]
[PubMed]
23. Yoshikawa, K.; Santo, K.; Hizaki, H.; Hashimoto, M. Effect of quantitative intraocular pressure reduction on visual field defect
progression in normal tension glaucoma under medical therapy applying Markov model. Clin. Ophthalmol. 2018, 12, 1617–1624.
[CrossRef] [PubMed]
24. Anderson, D.R.; Normal Tension Glaucoma Study. Collaborative normal tension glaucoma study. Curr. Opin. Ophthalmol. 2003,
14, 86–90. [CrossRef] [PubMed]
J. Clin. Med. 2021, 10, 2717 12 of 12
25. Kim, M.; Kim, D.M.; Park, K.H.; Kim, T.W.; Jeoung, J.W.; Kim, S.H. Intraocular pressure reduction with topical medications and
progression of normal-tension glaucoma: A 12-year mean follow-up study. Acta Ophthalmol. 2013, 91, e270–e275. [CrossRef]
26. Wang, S.Y.; Singh, K. Management of the glaucoma patient progressing at low normal intraocular pressure. Curr. Opin. Ophthalmol.
2020, 31, 107–113. [CrossRef] [PubMed]
27. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field
deterioration. The AGIS Investigators. Am. J. Ophthalmol. 2000, 130, 429–440. [CrossRef]
28. Montesano, G.; Quigley, H.A.; Crabb, D.P. Improving the power of glaucoma neuroprotection trials using existing visual field
data. Am. J. Ophthalmol. 2021, 24. [CrossRef]
29. Crabb, D.P.; Garway-Heath, D.F. Intervals between visual field tests when monitoring the glaucomatous patient: Wait-and-see
approach. Investig. Ophthalmol. Vis. Sci. 2012, 53, 2770–2776. [CrossRef]
30. Leske, M.C.; Heijl, A.; Hussein, M.; Bengtsson, B.; Hyman, L.; Komaroff, E.; Early Manifest Glaucoma Trial Group. Factors
for glaucoma progression and the effect of treatment: The early manifest glaucoma trial. Arch. Ophthalmol. 2003, 121, 48–56.
[CrossRef]
31. Heijl, A.; Buchholz, P.; Norrgren, G.; Bengtsson, B. Rates of visual field progression in clinical glaucoma care. Acta Ophthalmol.
2013, 91, 406–412. [CrossRef]
32. Han, J.C.; Han, S.H.; Park, D.Y.; Lee, E.J.; Kee, C. Clinical Course and Risk Factors for Visual Field Progression in Normal-Tension
Glaucoma with Myopia Without Glaucoma Medications. Am. J. Ophthalmol. 2020, 209, 77–87. [CrossRef]
33. Razeghinejad, M.R.; Lee, D. Managing normal tension glaucoma by lowering the intraocular pressure. Surv. Ophthalmol. 2019, 64,
111–116. [CrossRef]
34. Kim, H.W.; Choi, Y.J.; Lee, K.W.; Lee, M.J. Periorbital changes associated with prostaglandin analogs in Korean patients. BMC
Ophthalmol. 2017, 17, 126. [CrossRef]
35. Kim, J.W. Topical prostaglandin analogue drugs inhibit adipocyte differentiation. Korean J. Ophthalmol. 2014, 28, 257–264.
[CrossRef]
36. McClelland, J.F.; Bodle, L.; Little, J.A. Investigation of medication adherence and reasons for poor adherence in patients on
long-term glaucoma treatment regimes. Patient Prefer. Adherence 2019, 12, 431–439. [CrossRef]
37. Perez, C.I.; Singh, K.; Lin, S. Relationship of lifestyle, exercise, and nutrition with glaucoma. Curr. Opin. Ophthalmol. 2019, 30,
82–88. [CrossRef]
